Novo Nordisk A/S (OCSE:NOVO B)
kr 903.3 -9.6 (-1.05%) Market Cap: 4.02 Til Enterprise Value: 4.04 Til PE Ratio: 45.38 PB Ratio: 40.75 GF Score: 93/100

Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call Transcript

Nov 18, 2019 / 01:00PM GMT
Release Date Price: kr191.63 (-1.84%)
Operator

Good morning, ladies and gentlemen. And welcome to the Dicerna Pharmaceuticals Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded at the company's request.

I will now turn the call over to your host, [Abby Weissman], representing Dicerna Pharmaceuticals. Please go ahead.

Unidentified Participant

Thank you, operator. Good morning, everyone, and thank you for joining us for Dicerna's corporate update related to its collaboration with Novo Nordisk announced earlier this morning.

This morning, Dicerna and Novo Nordisk issued a press release announcing the companies have entered an agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases. The press release may be found under the Investors & Media tab on our website at www.dicerna.com. You may also listen to this conference call via webcast on our website, which will be archived for 30 days, beginning approximately 2 hours after the call is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot